Technology Center NovaMedica Innotech

NovaMedica started operation of the Technology Center designed for the development and pilot production of innovative drug products in April 2017. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.  

Technology Center’s R&D labs were put into operation in the end of 2016 and now they are already working under five projects within the own NovaMedica research program. Further four projects are to start in the course of the year. These drugs have innovative delivery system of active ingredients, which changes bioavailability of drugs and allows to combine incompatible previously substances in one dosage form. As a result, drugs under development will obtain new administration possibilities and they fundamentally surpass a number of analogue drugs in efficacy and safety.

Investments into creation of the center located in the Technopolis “Moscow” amounted to 945 mln RUB. The facilities of the center allow to carry out 15-20 R&D projects and produce up to 80 mln product units per year. Innovative developments will be patented and promoted not only in Russia, but also in the global market. NovaMedica plans to develop its scientific cooperation with leading Russian and international pharmaceutical companies, scientific and technological centers, universities and start-ups.

The development of the portfolio of its own drugs is a significant but not the only task of the NovaMedica Technology Center. The company plans to cooperate with foreign and local partners and to fulfil their drug development orders. The global market of pharmaceutical R&D-services equals to $8-10 bln per year, the Russian one, growing by 15-20% annually, amounts to approximately 1 billion RUB. NovaMedica intends to occupy about 20% of the Russian market by 2022.  

Anatoly Chubais, Chairman of the Executive Board of the Managing Company RUSNANO

Today we are launching a facility which without exaggeration can be associated with “Big Pharma”. State-of-the-art equipment is installed here and this allows to perform researches on the level previously unobtainable in Russia. Drug products to be produced here were developed by the major international producers. However, the fundamental difference of NovaMedica is that we are not going to produce just generics as many do, the laboratory complex allows to carry out own developments. In particular I would like to note the role of the Moscow authorities. It would be much more complicated for us without their support and without the infrastructure complex created in the Technopolis.”

Leonid Melamed, Member of the Board of Directors of NovaMedica

“Creation of the Technology Center will significantly speed up the process of development and market launch of the local innovative drug products. However, it is necessary to work in all directions to flood the Russian market with drugs which are highly required by the Russian patients. Today we have launched the Technology Center in Moscow and already in May within the frames of NovaMedica and Pfizer partnership we are going to commence construction of the GMP-plant for the sterile injection drug production in the Kaluga region. More than 30 drugs of vital importance to cure severe bacterial and fungal infections, cardiovascular, inflammatory and oncological diseases will be localized at this plant.”


NovaMedica Innotech, LLC carries out the process of creation and development of the Technology Center. It is a R&D division of NovaMedica which was established to develop new drug products and to transfer intellectual property rights (100% subsidiary of NovaMedica LLC, and a participant of Skolkovo Foundation since July 2013).

Shareholders

Read more

Pipeline

Read more

Media Center

Read more